This prospective, observational multicentre (n= 24) study investigated relationships between
antimicrobial choices and rates of empiric appropriate or adequate therapy, and subsequent …

Data of developmental pharmacokinetics (PK) of meropenem in critically ill infants and
children with severe infections are limited. We assessed the population PK and defined the …

Severe sepsis is an important cause of mortality and morbidity in critically ill children.
Meropenem is a broad‐spectrum antibiotic commonly used to treat sepsis. Current …

OBJECTIVE This study aims to describe the population pharmacokinetics and
pharmacodynamic target attainment of meropenem in critically ill children. METHODS The …

Objective To compare the efficacy and tolerability of meropenem and imipenem/cilastatin as
empirical monotherapy in intensive care unit (ICU) patients with serious bacterial infections …

Background: Meropenem plays a significant role in the current antimicrobial treatment of
serious infections. Recently, generic meropenems have become widely available in …

Objective: In Siriraj Hospital, generic meropenem (Monem®) has been available and was
substituted for original meropenem, but the effectiveness and safety of using generic …

Objective To collate the clinical response and pathogen eradication rates for meropenem
monotherapy with in vitro susceptibility of the causative pathogens. Methods Data were …

Meropenem is a parenteral carbapenem that has been used clinically since 1994. Since the
first review of its safety profile in 1995, the patient database has increased substantially. This …

What is known and Objective Meropenem, a broad‐spectrum carbapenem, is frequently
used to treat severe bacterial infections in critically ill children. Recommendations for …